Estradiol valerate/methenmadinone caproate (EV/MMC), known by the tentative brand name Lutofollin, is a combination medication of estradiol valerate (EV), an estrogen, and methenmadinone caproate (MMC; superlutin caproate), a progestin, which was developed for potential use as a once-a-month combined injectable contraceptive but was never marketed.[1][2][3] It contained 10 mg EV and 60 mg MMC in 1 mL oil solution and was intended for administration by intramuscular injection once every 4 weeks.[1][2][3]
 | |
 | |
| Combination of | |
|---|---|
| Estradiol valerate | Estrogen |
| Methenmadinone caproate | Progestogen |
| Clinical data | |
| Other names | EV/MMC; Lutofollin |
| Routes of administration | Intramuscular injection |
| Identifiers | |
| CAS Number | |
See also
editReferences
edit- ^ a b Stĕrba R (January 1976). "Tschechoslowakisches Injektionskontrazeptivum, einmal im Monat zu verabreichen" [A Czechoslovak injection-contraceptive agent administered once a month]. Zentralblatt für Gynakologie (in German). 98 (3): 158–160. ISSN 0044-4197. PMID 970015.
- ^ a b Mokhtar K. Toppozada (1983), Monthly Injectable Contraceptives
- ^ a b Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |